查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1977203

医药和生物技术领域临床阶段合作条款及协议（2020-2026）

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026
出版日期: | 出版商: Current Partnering | 英文 1000+ Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告对医药和生物技术领域的临床阶段合作条款及协议进行了全面、数据驱动的分析，深入剖析了企业签订临床阶段合作协议的背景和原因，以及影响这些合作的财务和战略因素。这份产业必备的资源提供了关于临床阶段药物研发合作中合约结构、谈判动态和财务考量的独到见解。

临床阶段授权协议通常授予被授权人独家开发授权人产品或技术的权利或选择权，通常涵盖I期、II期和III期临床试验。这些协议往往形式复杂，包含联合研发、共同开发和商业化策略等多个要素。

本报告详细介绍了医疗保健领域最新的临床阶段协议，帮助企业评估市场趋势、优化谈判策略并建立合约结构基准。

生技与製药业经销商的必备资源

"製药和生物技术领域临床阶段合作条款和协议" 报告是参与生物製药交易的业务拓展、法律和财务专业人士不可或缺的资讯来源。

凭藉全面的洞察、庞大的交易资料库以及对合约文件的直接访问，本报告是以下用途的终极工具：

  • 交易结构与财务条款基准分析
  • 优化谈判策略
  • 评估潜在合作伙伴的弹性
  • 识别临床阶段合作的趋势
  • 为什么本报告对经销商至关重要
  • 在建立临床阶段合作关係时，了解潜在合作伙伴的灵活性和谈判策略至关重要。主要财务条款（例如，预付款、里程碑付款、特许权使用费）只是概要；合约文件明确规定了这些付款的实际触发条件和条件，而这些细节往往在新闻稿和传统交易资料库中缺失。
  • 本报告全面涵盖了自 2020 年以来发布的 1,859 份临床阶段合作协议，包括可用的财务条款。报告还提供了指向线上合约记录和向美国证券交易委员会 (SEC) 提交的公开合约文件的直接连结。
  • 分析这些协议能够帮助企业获得关键讯息，从而优化其交易策略、评估合作伙伴的灵活性并制定具有竞争力的合约。
  • 临床阶段合作趋势的全面分析

本报告的第一章详细解释了临床阶段合作的运作方式。内容如下：

第一章 - 本报告简介

第二章 - 企业为何参与临床阶段合作

第三章 - 策略方法与合约结构（附个案研究）

第四章 - 付款策略，包括预付款、里程碑付款和特许权使用费

第五章 - 依年份、研发阶段、治疗领域、技术类型和主要承包商分析临床阶段合约活动

第六章 - I期、II期和III期合约的总金额、预付款、里程碑完成条件和特许权使用费率的详细财务分析

第七章 - 主要临床阶段合约的总金额回顾

第八章 - 顶尖承包商简介 25家最活跃的临床阶段交易管理公司

第九章 - 临床阶段合作协议资料库（包括可用合约文件）

第十章 - 依I期、II期和III期分类的临床阶段协议综合目录

  • 本报告的主要优势

这份产业必备资源提供独家见解，帮助企业评估、建构和谈判其临床阶段合作。主要优点包括：

  • 无与伦比的市场洞察 - 深入了解塑造2020年后製药和生物技术产业的临床阶段交易趋势。
  • 取得独家财务数据 - 透过取得合约总价值、预付款、里程碑付款结构和特许权使用费条款等信息，在合约谈判中获得竞争优势。
  • 全面的合约资料库 - 存取 1,859 份精心挑选的临床阶段协议（包括可用的合约文件），提供无与伦比的透明度和基准分析。
  • 深入分析产业领导者 - 分析全球排名前 25 名的製药、生物技术和新兴生物製药公司实际签署的临床阶段协议。
  • 经过验证的案例研究和结构分析 - 验证真实世界的合约结构和案例研究，以完善您自身的合作和谈判策略。
  • 识别高价值交易 - 识别自 2020 年以来达成的最具盈利性的临床阶段协议，并深入了解行业中的优质交易。
  • 分析最活跃的交易撮合者 - 识别推动临床阶段合作的关键人物，确保您找到合适的合作伙伴。
  • 策略交易地图 - 全面了解临床阶段协议，并依公司、研发阶段、交易类型、治疗领域和技术重点进行分类。
  • 自信谈判 - 了解顶级公司在以往交易中达成的关键条款，助您建立最优合约。
  • 强有力的尽职调查支援 - 进行数据驱动的评估，以确定拟议交易条款对潜在合作伙伴的可行性和竞争力。
  • 研究范围

本报告 "製药和生物技术领域的临床阶段合作条款和协议" 提供以下内容：

  • 2020年以来生物製药产业临床阶段合约签署趋势
  • 详细的合约结构（包括预付款、里程碑付款和特许权使用费条款）
  • 实际临床阶段合约案例研究
  • 访问超过1670项临床阶段交易（在有合约记录的情况下）
  • 2020年以来最活跃的临床阶段交易方简介
  • 最高价值临床阶段交易分析

每笔合约记录的索引如下：

  • 公司名称（依字母顺序排列）
  • 交易总价值
  • 合约签署时的研发阶段（I期、II期、III期）
  • 交易类型
  • 特定治疗领域
  • 关键问题解答

本报告透过分析实际合同，清楚解答了以下关键问题：

  • 每份合约授予了哪些具体权利？
  • 适用哪些排他性条款？
  • 合约的财务结构是什么？ （预付款、里程碑付款、特许权使用费）
  • 谁负责开发、生产和商业化？
  • 如何处理知识产权？
  • 合约的终止条件是什么？
  • 有哪些争议解决机制？
  • 如何管理保密权和出版权？
  • 阅读本报告，帮助您获得竞争优势。

目录

摘要整理

第一章：引言

第二章：企业为何与临床阶段化合物合作

  • 引言
  • 合作在临床阶段开发中的作用
    • 临床阶段开发中的许可
    • 临床阶段开发中的许可
  • I期、II期及III期交易的差异
  • 签订临床阶段合作协议的原因
    • 授权人签订临床阶段交易的原因
    • 被授权人签订临床阶段交易的原因
  • 临床阶段合作协议的未来

章节3 临床阶段交易策略与架构

  • 引言
  • 企业在哪个阶段开展合作？
    • 製药/生技领域的早期合作
    • 製药/生技领域的合作
  • 早期与后期合作－风险与成本比较
  • 企业在临床阶段合作上投入多少资金？
  • 纯粹授权和多组件合作协议
  • 纯粹授权协议结构
    • 纯粹授权协议范例
    • 个案研究 9
    • 个案研究 10
  • 多组件临床阶段合作协议
    • 包含多个组件的临床阶段条款范例
    • 个案研究 11

第四章 临床阶段的合作支付策略

  • 引言
  • 临床阶段的支付策略
  • 付款方式
    • 主要内容
    • 预付款
    • 贷款
    • 转换贷款
    • 公平性
    • 研发资金
    • 许可费
    • 里程碑付款付款方式
    • 特许权使用费支付
    • Quids
    • 可选付款方式

第五章 临床阶段交易趋势

  • 引言
  • 长期临床阶段合作关係
    • 2020年以来I期临床试验交易趋势
    • 2020年以来第二期临床试验交易趋势
    • 2020年以来III期临床试验交易趋势
  • 依交易类型划分的临床阶段合作关係
  • 依疾病区分的临床阶段合作关係
  • 依技术类型划分的临床阶段合作关係
  • 2020年以来最活跃公司划分的临床阶段合作关係

第六章 临床阶段合作关係中的付款条款

  • 引言
  • 临床阶段付款指引条款
    • 预付款
    • 里程碑付款
    • 特许权使用费
  • 临床阶段付款条款 - 交易资料分析
    • 公开数据
    • 调查数据
  • 付款条款分析
    • 临床阶段合作项目总价值
    • 临床阶段协议的合约预付款
    • 临床阶段交易的里程碑付款
    • 临床阶段交易的特许权使用费率
  • 临床阶段交易的财务中位数
    • 临床阶段交易的总价值
    • 临床阶段交易的初始价值
    • 临床阶段交易的里程碑价值
    • 临床阶段交易的特许权使用费

第七章 领先的临床阶段交易

  • 引言
  • 依金额排列的关键临床阶段交易

第八章 - 拥有临床阶段合约的前 25 家公司

  • 引言
  • 临床阶段合约最活跃的前 25 家公司

第九章 临床阶段合作协议目录

  • 引言
  • 临床阶段交易数据来自 2020 年

第十章 依研发阶段划分的临床阶段交易

  • 引言
  • 依临床阶段划分的交易
  • I 期
  • II 期
  • III 期
  • 法规

附录

  • 附录 1 - 依公司（AZ）划分的临床阶段交易
  • 附录 2 - 依产业划分的临床阶段交易
  • 附录 3 - 依研发阶段划分的临床阶段交易
  • 附录 4 - 依治疗领域划分的临床阶段交易
  • 附录 5 - 依技术类型划分的临床阶段交易
  • 关于研究公司
  • 当前合作关係
  • 当前交易
  • 来自 "目前合作关係" 的最新报告标题
简介目录
Product Code: CP2058

The Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology report provides a comprehensive, data-driven analysis of how and why companies engage in clinical-stage partnering agreements, as well as the financial and strategic terms shaping these collaborations. This essential industry resource delivers unparalleled insights into deal structures, negotiation dynamics, and financial considerations for clinical-stage drug development partnerships.

At the clinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's product or technology, often covering Phase I, Phase II, and Phase III trials. These agreements are frequently multi-component, involving collaborative R&D, co-development, and commercialization strategies.

This report provides detailed intelligence on the latest clinical-stage agreements in the healthcare sector, helping companies evaluate market trends, optimize negotiation strategies, and benchmark deal structures.

A Must-Have Resource for Biotech and Pharma Dealmakers

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.

With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:

  • Benchmarking deal structures and financial terms
  • Optimizing negotiation strategies
  • Assessing potential partners' flexibility
  • Identifying trends in clinical-stage partnerships
  • Why This Report is Essential for Dealmakers
  • Understanding the flexibility and negotiation strategies of potential partners is critical when structuring clinical-stage partnerships. While headline financial terms (e.g., upfront payments, milestones, royalties) provide a broad overview, contract documents reveal the actual triggers and conditions for these payments-details often missing from press releases and traditional deal databases.
  • This report provides a comprehensive listing of over 1,859 clinical-stage deals announced since 2020, including financial terms where available. Additionally, it features direct links to online deal records, along with publicly available contract documents submitted to the SEC.
  • By analyzing these agreements, companies can gain critical insights to refine deal strategies, assess partner flexibility, and structure competitive agreements.
  • Comprehensive Analysis of Clinical-Stage Partnering Trends

The first chapters of this report offer a detailed orientation to clinical-stage deal-making, including:

Chapter 1 - Introduction to the report

Chapter 2 - Why companies engage in clinical-stage partnerships

Chapter 3 - Strategic approaches and deal structures, with case studies

Chapter 4 - Payment strategies, including upfronts, milestones, and royalties

Chapter 5 - Analysis of clinical-stage deal activity categorized by year, stage of development, therapeutic area, technology type, and key dealmakers

Chapter 6 - In-depth financial analysis of headline values, upfront payments, milestone triggers, and royalty rates for Phase I, Phase II, and Phase III deals

Chapter 7 - A review of the leading clinical-stage deals by headline value

Chapter 8 - Profiles of the top 25 most active clinical-stage dealmakers

Chapter 9 - A database of clinical-stage partnering agreements, including contract documents where available

Chapter 10 - A comprehensive directory of all clinical-stage deals categorized by Phase I, Phase II, and Phase III

  • Key Benefits of the Report

This must-have industry resource provides exclusive insights to help companies assess, structure, and negotiate their own clinical-stage partnerships. Key benefits include:

  • Unparalleled Market Insights - Gain a deep understanding of clinical-stage deal trends shaping the pharma and biotech industry since 2020.
  • Exclusive Financial Data Access - Unlock headline values, upfront payments, milestone structures, and royalty terms, giving you a competitive edge in deal negotiations.
  • Comprehensive Deal Database - Access a curated repository of 1,859 clinical-stage agreements, including contract documents where available, for unmatched transparency and benchmarking.
  • Deep-Dive into Industry Leaders - Analyze actual clinical-stage deals entered into by the top 25 global pharma and biotech companies, alongside emerging biopharma players.
  • Proven Case Studies & Structural Analysis - Examine real-world deal structures and case studies to refine your own partnering and negotiation strategies.
  • High-Value Deal Identification - Pinpoint the most lucrative clinical-stage deals signed since 2020, gaining insight into premium industry transactions.
  • Profile the Most Active Dealmakers - Identify the key players driving clinical-stage collaborations, ensuring you target the right partners.
  • Strategic Deal Mapping - Navigate a full A-Z listing of clinical-stage agreements, categorized by company, development phase, deal type, therapeutic area, and technology focus.
  • Negotiate with Confidence - Understand the key terms and conditions top-tier companies have agreed to in previous deals, helping you structure optimal agreements.
  • Robust Due Diligence Support - Conduct data-backed assessments to determine the viability and competitiveness of your proposed deal terms with potential partners.
  • Report Scope

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides:

  • Trends in clinical-stage dealmaking in the biopharma industry since 2020
  • Detailed deal structures, including upfront, milestone, and royalty terms
  • Case studies of real-life clinical-stage agreements
  • Access to over 1,670 clinical-stage deals, with contract records where available
  • Partnering profiles of the most active clinical-stage dealmakers since 2020
  • Analysis of the highest-value clinical-stage deals

Each deal record is indexed by:

  • Company (A-Z)
  • Headline Value
  • Stage of Development at Signing (Phase I, Phase II, Phase III)
  • Deal Type
  • Specific Therapy Focus
  • Critical Questions Answered

By analyzing actual contract agreements, this report provides definitive answers to critical questions such as:

  • What specific rights are granted in each agreement?
  • What exclusivity terms apply?
  • How is the deal structured financially? (Upfronts, milestones, royalties)
  • Who controls development, manufacturing, and commercialization?
  • How are intellectual property rights handled?
  • What are the termination conditions for the agreement?
  • What dispute resolution mechanisms are in place?
  • How are confidentiality and publication rights managed?
  • Gain the competitive edge-explore the report today.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner clinical stage compounds?

  • 2.1. Introduction
  • 2.2. The role of clinical stage partnering
    • 2.2.1. In-licensing at clinical stage
    • 2.2.2. Out-licensing at clinical stage
  • 2.3. Difference between phase I, II and III stage deals
  • 2.4. Reasons for entering into clinical stage partnering deals
    • 2.4.1. Licensors reasons for entering clinical stage deals
    • 2.4.2. Licensees reasons for entering clinical stage deals
  • 2.5. The future of clinical stage partnering deals

Chapter 3 - Clinical stage deal strategies and structure

  • 3.1. Introduction
  • 3.2. At what stage do companies partner?
    • 3.2.1. Partnering early in pharmaceutical/biotech
    • 3.2.1.1. Discovery and preclinical stage partnering case studies
    • 3.2.1.1.a. Case study 1
    • 3.2.1.1.b. Case study 2
    • 3.2.1.1.c. Case study 3
    • 3.2.1.1.d. Case study 4
    • 3.2.2. Partnering later in pharmaceutical/biotech
    • 3.2.2.1. Clinical stage partnering case studies
    • 3.2.2.1.a. Case study 5
    • 3.2.2.1.b. Case study 6
    • 3.2.2.1.c. Case study 7
    • 3.2.2.1.d. Case study 8
  • 3.3. Early and later stage partnering - a risk/cost comparison
  • 3.4. What do companies spend on clinical stage partnering?
  • 3.5. Pure versus multi-component partnering deals
  • 3.6. Pure licensing agreement structure
    • 3.6.1. Example pure licensing agreements
    • 3.6.1.a. Case study 9
    • 3.6.1.b. Case study 10
  • 3.7. Multicomponent clinical stage partnering agreements
    • 3.7.1. Example multicomponent clinical stage clauses
    • 3.7.1.a. Case study 11

Chapter 4 - Clinical stage partnering payment strategies

  • 4.1. Introduction
  • 4.2. Clinical stage payment strategies
  • 4.3. Payment options
    • 4.3.1. Headline values
    • 4.3.2. Upfront payments
    • 4.3.2.1. Conditionality of upfront payments
    • 4.3.3. Loans
    • 4.3.4. Convertible loans
    • 4.3.5. Equity
    • 4.3.6. R&D funding
    • 4.3.7. Licensing fees
    • 4.3.8. Milestone payments
    • 4.3.9. Royalty payments
    • 4.3.9.1. Issues affecting royalty rates
    • 4.3.9.2. Royalties on combination products
    • 4.3.9.2.a. Case study 12
    • 4.3.9.3. Guaranteed minimum/maximum annual payments
    • 4.3.9.4. Royalty stacking
    • 4.3.9.5. Royalties and supply/purchase contracts
    • 4.3.10. Quids
    • 4.3.11. Option payments

Chapter 5 - Trends in clinical stage deal making

  • 5.1. Introduction
  • 5.2. Clinical stage partnering over the years
    • 5.2.1. Trends in phase I deals since 2020
    • 5.2.1.1. Attributes of phase I deals
    • 5.2.2. Trends in phase II deals since 2020
    • 5.2.2.2. Attributes of phase II deals
    • 5.2.3. Trends in phase III deals since 2020
    • 5.2.3.1. Attributes of phase III deals
  • 5.3. Clinical stage partnering by deal type
  • 5.4. Clinical stage partnering by disease type
  • 5.5. Partnering by clinical stage technology type
  • 5.6. Clinical stage partnering by most active company since 2020

Chapter 6 - Payment terms for clinical stage partnering

  • 6.1. Introduction
  • 6.2. Guidelines for clinical stage payment terms
    • 6.2.1. Upfront payments
    • 6.2.2. Milestone payments
    • 6.2.3. Royalty payments
  • 6.3. Clinical stage payment terms - deal data analysis
    • 6.3.1. Public data
    • 6.3.2. Survey data
  • 6.4. Payment terms analysis
    • 6.4.1. Clinical stage partnering headline values
    • 6.4.2. Clinical stage deal upfront payments
    • 6.4.3. Clinical stage deal milestone payments
    • 6.4.4. Clinical stage royalty rates
  • 6.5 Clinical stage median financials
    • 6.5.1. Clinical stage headline value
    • 6.5.2. Clinical stage upfront value
    • 6.5.3. Clinical stage milestone value
    • 6.5.4. Clinical stage royalty value

Chapter 7 - Leading clinical stage deals

  • 7.1. Introduction
  • 7.2. Top clinical stage deals by value

Chapter 8 - Top 25 most active clinical stage dealmakers

  • 8.1. Introduction
  • 8.2. Top 25 most active clinical stage dealmakers

Chapter 9 - Clinical stage partnering contracts directory

  • 9.1. Introduction
  • 9.2. Clinical stage deals with contracts since 2020

Chapter 10 - Clinical stage deal making by development stage

  • 10.1. Introduction
  • 10.2. Deals by clinical stage
  • Phase I
  • Phase II
  • Phase III
  • Regulatory

Appendices

  • Appendix 1 - Clinical stage dealmaking by companies A-Z
  • Appendix 2 - Clinical stage dealmaking by industry sector
  • Appendix 3 - Clinical stage dealmaking by stage of development
  • Appendix 4 - Clinical stage dealmaking by therapy area
  • Appendix 5 - Clinical stage dealmaking by technology type
  • About Biopharma Research Ltd
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Definition of clinical phases in dealmaking
  • Figure 2: Components of the pure licensing deal structure
  • Figure 3: Payment options for clinical stage partnering deals
  • Figure 4: Issues affecting royalty rates
  • Figure 5: Clinical stage partnering by deal type
  • Figure 6: Clinical stage partnering by disease type
  • Figure 7: Clinical stage partnering by technology type
  • Figure 8: Top 25 most active clinical stage dealmakers
  • Figure 9: Review of upfront payments for clinical stage deals
  • Figure 10: Review of milestone payments for clinical stage deals
  • Figure 11: Review of royalty payments for clinical stage deals
  • Figure 12: Clinical stage deals with a headline value
  • Figure 13: Clinical stage deals with an upfront value
  • Figure 14: Clinical stage deals with a milestone value
  • Figure 15: Clinical stage deals with a royalty rate value
  • Figure 16: Top clinical stage deals by value
  • Figure 17: Most active clinical stage dealmakers